Scribe Therapeutics Prepares for Clinical Trials by Streamlining Workforce Amid Advances in Cardiometabolic Genetic Medicines
Workforce Reduction:
Scribe Therapeutics is reducing its workforce by 20% as it prepares its cardiometabolic pipeline for clinical trials24.
Technological Advances:
The company has made significant preclinical progress with its CRISPR-based genome editing and epigenetic modifying technologies, demonstrating durable reductions in LDL-C levels and triglycerides in non-human primates and mice13.
Clinical Potential:
Scribe’s technologies, including CRISPR X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR), have shown potential to safely and effectively treat major cardiometabolic diseases, such as atherosclerotic cardiovascular disease (ASCVD) and hypertriglyceridemia13.
Future Plans:
The company expects to have further updates on its clinical progress in 2025, aiming to lead the industry in developing safer and more effective genetic therapies for cardiometabolic diseases13.
Industry Impact:
Scribe’s advancements could revolutionize the treatment of cardiometabolic diseases, offering once-in-a-lifetime therapies that fundamentally lower major risks associated with these conditions5.
Sources:
1. https://www.insideprecisionmedicine.com/topics/translational-research/scribe-therapeutics-verifies-in-vivo-crispr-based-cardiometabolic-therapies/
2. https://www.cafepharma.com/content/scribe-slims-down-workforce-it-readies-cardiometabolic-genetic-meds-clinic
3. https://www.businesswire.com/news/home/20241122617151/en/Scribe-Therapeutics-Reports-Preclinical-Data-Validating-its-CRISPR-Genome-Editing-and-Epigenome-Modifying-Technologies-for-Addressing-Cardiometabolic-Disease-at-American-Heart-Association-AHA-Scientific-Sessions-2024